We are live on ! Find out more
ELI

ELITE PHARMACEUTICAL
ELI

Delisted

ELI was delisted on the 20th of May, 2009.

Back to rankings

1 hedge funds and large institutions have $180 invested in ELITE PHARMACEUTICAL in 2026 Q1 according to their latest regulatory filings, with funds opening new positions, increasing their positions, reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 1 → 1 (0)

27% less capital invested

Capital invested by funds: $245 → $180 (-$65)

Holders
1
Holders Change
–
Holders Change %
0%
% of All Funds
0.01%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

No sellers this quarter

ELI Hedge Fund Activity: Q1 2026 in Review

1 of the 8,191 institutional investors tracked by Wall St. Rank reported a position in ELITE PHARMACEUTICAL (ELI) for Q1 2026, worth a combined $180 — down 27% from $245 a quarter earlier.

Fund positioning in ELI was balanced in Q1 2026: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 0 trimmed.

  • 1 institutional investor held ELITE PHARMACEUTICAL (ELI) as of Q1 2026, unchanged from Q4 2025.
  • Funds reported $180 of ELITE PHARMACEUTICAL stock for Q1 2026, down 27% quarter-over-quarter.
  • 0 funds opened new ELITE PHARMACEUTICAL positions in Q1 2026 and 0 closed out.

Based on aggregated 13F filings for Q1 2026.